BR112022016580A2 - Composições e métodos para induzir uma resposta imune - Google Patents
Composições e métodos para induzir uma resposta imuneInfo
- Publication number
- BR112022016580A2 BR112022016580A2 BR112022016580A BR112022016580A BR112022016580A2 BR 112022016580 A2 BR112022016580 A2 BR 112022016580A2 BR 112022016580 A BR112022016580 A BR 112022016580A BR 112022016580 A BR112022016580 A BR 112022016580A BR 112022016580 A2 BR112022016580 A2 BR 112022016580A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- inducing
- compositions
- immune response
- viral vector
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPOSIÇÕES E MÉTODOS PARA INDUZIR UMA RESPOSTA IMUNE. A invenção refere-se a uma composição que compreende um vetor viral, sendo que o vetor viral compreende ácido nucleico que tem uma sequência polinucleotídica que codifica a proteína spike do coronavírus SARS-CoV2, caracterizada pelo fato de que o dito vetor viral é um vetor à base de adenovírus. A invenção também se refere a usos de tal composição e métodos de tratamento.
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2003670.3A GB202003670D0 (en) | 2020-03-13 | 2020-03-13 | Compositions and methods for inducing an immune response |
GBGB2006608.0A GB202006608D0 (en) | 2020-05-05 | 2020-05-05 | Compositions and methods for inducing an immune response |
GBGB2007062.9A GB202007062D0 (en) | 2020-05-13 | 2020-05-13 | Compositions and methods for inducing an immune response |
GBGB2009239.1A GB202009239D0 (en) | 2020-06-17 | 2020-06-17 | Compositions and methods for inducing an immune response |
GBGB2010569.8A GB202010569D0 (en) | 2020-07-09 | 2020-07-09 | Compositions and methods for inducing an immune response |
GBGB2016922.3A GB202016922D0 (en) | 2020-10-26 | 2020-10-26 | Compositions and methods for inducing an immune response |
GBGB2017284.7A GB202017284D0 (en) | 2020-10-30 | 2020-10-30 | Compositions and methods for inducing an immune response |
GBGB2017677.2A GB202017677D0 (en) | 2020-11-09 | 2020-11-09 | Compositions and methods for inducing an immune response |
GBGB2018410.7A GB202018410D0 (en) | 2020-11-23 | 2020-11-23 | Compositions and Methods for Inducing an Immune Response |
GBGB2018718.3A GB202018718D0 (en) | 2020-11-27 | 2020-11-27 | Compositions and methods for inducing an immune response |
GBGB2100034.4A GB202100034D0 (en) | 2021-01-04 | 2021-01-04 | Compositions and methods for inducing an immune response |
PCT/GB2021/050602 WO2021181100A1 (en) | 2020-03-13 | 2021-03-11 | Compositions and methods for inducing an immune response |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022016580A2 true BR112022016580A2 (pt) | 2022-11-16 |
Family
ID=75108658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022016580A BR112022016580A2 (pt) | 2020-03-13 | 2021-03-11 | Composições e métodos para induzir uma resposta imune |
Country Status (19)
Country | Link |
---|---|
US (1) | US20230285532A1 (pt) |
EP (1) | EP4117723A1 (pt) |
JP (1) | JP2023517286A (pt) |
KR (1) | KR20220152248A (pt) |
CN (1) | CN115720522A (pt) |
AU (1) | AU2021235248A1 (pt) |
BR (1) | BR112022016580A2 (pt) |
CA (1) | CA3171939A1 (pt) |
CL (1) | CL2022002420A1 (pt) |
CO (1) | CO2022011811A2 (pt) |
CR (1) | CR20220501A (pt) |
DO (1) | DOP2022000184A (pt) |
EC (1) | ECSP22076973A (pt) |
IL (1) | IL295630A (pt) |
MX (1) | MX2022011394A (pt) |
PE (1) | PE20221758A1 (pt) |
TW (1) | TW202200198A (pt) |
UY (1) | UY39131A (pt) |
WO (1) | WO2021181100A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2022013254A (es) | 2020-04-22 | 2023-01-24 | BioNTech SE | Vacuna contra el coronavirus. |
WO2023026182A1 (en) * | 2021-08-24 | 2023-03-02 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
WO2023135439A1 (en) * | 2022-01-17 | 2023-07-20 | Institut Pasteur | Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine |
GB202201768D0 (en) * | 2022-02-11 | 2022-03-30 | Virax Biolabs Uk Ltd | Peptides |
GB202201765D0 (en) * | 2022-02-11 | 2022-03-30 | Virax Biolabs Uk Ltd | Methods |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0706914D0 (en) | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel adenovirus vectors |
GB201006405D0 (en) | 2010-04-16 | 2010-06-02 | Isis Innovation | Poxvirus expression system |
GB201108879D0 (en) | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
GB201708444D0 (en) * | 2017-05-26 | 2017-07-12 | Univ Oxford Innovation Ltd | Compositions and methods for inducing an immune response |
-
2021
- 2021-03-11 PE PE2022001921A patent/PE20221758A1/es unknown
- 2021-03-11 IL IL295630A patent/IL295630A/en unknown
- 2021-03-11 WO PCT/GB2021/050602 patent/WO2021181100A1/en active Application Filing
- 2021-03-11 AU AU2021235248A patent/AU2021235248A1/en active Pending
- 2021-03-11 EP EP21713080.6A patent/EP4117723A1/en active Pending
- 2021-03-11 CN CN202180016017.4A patent/CN115720522A/zh active Pending
- 2021-03-11 CA CA3171939A patent/CA3171939A1/en active Pending
- 2021-03-11 CR CR20220501A patent/CR20220501A/es unknown
- 2021-03-11 MX MX2022011394A patent/MX2022011394A/es unknown
- 2021-03-11 JP JP2022549978A patent/JP2023517286A/ja active Pending
- 2021-03-11 BR BR112022016580A patent/BR112022016580A2/pt unknown
- 2021-03-11 KR KR1020227034118A patent/KR20220152248A/ko unknown
- 2021-03-12 TW TW110109025A patent/TW202200198A/zh unknown
- 2021-03-12 US US17/200,297 patent/US20230285532A1/en active Pending
- 2021-03-15 UY UY0001039131A patent/UY39131A/es unknown
-
2022
- 2022-08-20 CO CONC2022/0011811A patent/CO2022011811A2/es unknown
- 2022-09-06 CL CL2022002420A patent/CL2022002420A1/es unknown
- 2022-09-12 DO DO2022000184A patent/DOP2022000184A/es unknown
- 2022-10-03 EC ECSENADI202276973A patent/ECSP22076973A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023517286A (ja) | 2023-04-25 |
CL2022002420A1 (es) | 2023-04-28 |
CO2022011811A2 (es) | 2022-08-30 |
CR20220501A (es) | 2023-01-23 |
TW202200198A (zh) | 2022-01-01 |
CN115720522A (zh) | 2023-02-28 |
ECSP22076973A (es) | 2022-12-30 |
US20230285532A1 (en) | 2023-09-14 |
MX2022011394A (es) | 2022-10-13 |
CA3171939A1 (en) | 2021-09-16 |
PE20221758A1 (es) | 2022-11-11 |
DOP2022000184A (es) | 2022-10-16 |
KR20220152248A (ko) | 2022-11-15 |
WO2021181100A1 (en) | 2021-09-16 |
UY39131A (es) | 2021-09-30 |
AU2021235248A1 (en) | 2022-09-01 |
IL295630A (en) | 2022-10-01 |
EP4117723A1 (en) | 2023-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022016580A2 (pt) | Composições e métodos para induzir uma resposta imune | |
BR112018003486A2 (pt) | ?molécula, rna, métodos para obter rna, métodos para obter um peptídeo e usos do rna? | |
BR112019010275A2 (pt) | adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano | |
BR112016029041A8 (pt) | uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico | |
BR112018011975A2 (pt) | composições úteis no tratamento de atrofia muscular espinhal | |
DOP2022000293A (es) | Análogos de nucleósido de 1-ciano y usos de los mismos | |
BR112017015773A2 (pt) | muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo | |
BR112019024813A2 (pt) | adenovírus recombinantes portando transgenes | |
BR112018013820A2 (pt) | análogos de egf(a) com substituintes de ácido graxo | |
BR112018070852A2 (pt) | composições de dissulfeto de selênio para uso no tratamento de disfunção das glândulas meibomianas | |
BR112018015696A2 (pt) | composições e métodos para gerar uma resposta imune para um flavivírus | |
CR20220618A (es) | Nuevas proteinas de unión a repeticiones de anquirina y sus usos | |
ECSP20057847A (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
BR112022026580A2 (pt) | Composições e métodos para induzir uma resposta imune contra coronavírus | |
BR112022012324A2 (pt) | Composições e métodos para modular simultaneamente expressão de genes | |
BR112021023832A2 (pt) | Métodos e composições para geração de óxido nítrico e usos dos mesmos | |
CL2023001062A1 (es) | Compuestos fosfolípidos y usos de estos | |
BR112018005271A2 (pt) | meios para o tratamento de hiv | |
BR112017013270A2 (pt) | ?composição de vacina contra vírus da dengue, métodos para induzir uma resposta imune contra dengue, para reduzir a probabilidade de infecção por dengue, ou prevenir ou atenuar os sintomas da mesma, e, uso de uma composição de vacina contra vírus da dengue?. | |
BR112019024750A2 (pt) | uso de glutamina sintetase no tratamento da hiperamonemia | |
BR112022004032A2 (pt) | Composições probióticas mixotróficas e usos das mesmas no tratamento de distensão abdominal | |
CL2023000146A1 (es) | Excipientes reductores de la viscosidad y combinaciones de los mismos para formulaciones proteicas altamente concentradas | |
AR122393A1 (es) | Composiciones y métodos para la inducción de una respuesta inmune | |
BR112019003181A2 (pt) | composição para aumentar uma resposta imune em animal, método para induzir uma resposta imune protetora em um sujeito, e, uso da composição na preparação de um medicamento. | |
BR112022023135A2 (pt) | Amidas tricíclicas substituídas, análogos das mesmas e métodos que usam as mesmas |